MLICM
SRNE

Metropolitan Life Insurance Company (MetLife)’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-28,609
Closed -$25.3K – 2520
2022
Q4 		$25.3K Buy
28,609
+11,028
+63% +$14.6K ﹤0.01% 1874
2022
Q3 		$27.6K Sell
17,581
-5,501
-24% -$12.5K ﹤0.01% 1838
2022
Q2 		$46.4K Buy
23,082
+3,901
+20% +$6.75K ﹤0.01% 1553
2022
Q1 		$44.7K Sell
19,181
-58,256
-75% -$182K ﹤0.01% 1658
2021
Q4 		$360K Buy
77,437
+4,537
+6% +$28.2K ﹤0.01% 1629
2021
Q3 		$556K Sell
72,900
-519
-0.7% -$4.4K 0.01% 1386
2021
Q2 		$711K Buy
73,419
+5,803
+9% +$46.2K 0.01% 1273
2021
Q1 		$559K Sell
67,616
-3,915
-5% -$41.3K 0.01% 1347
2020
Q4 		$488K Buy
71,531
+7,034
+11% +$56.5K 0.01% 1365
2020
Q3 		$719K Buy
64,497
+9,756
+18% +$89.3K 0.01% 947
2020
Q2 		$344K Buy
54,741
+10,837
+25% +$41.5K 0.01% 1467
2020
Q1 		$80.8K Buy
43,904
+1,182
+3% +$3.4K ﹤0.01% 2165
2019
Q4 		$144K Buy
42,722
+23,131
+118% +$55.1K ﹤0.01% 2122
2019
Q3 		$41.9K Sell
19,591
-13,546
-41% -$31.6K ﹤0.01% 2511
2019
Q2 		$88.5K Hold
33,137
– – ﹤0.01% 2369
2019
Q1 		$157K Buy
33,137
+2,926
+10% +$7.68K ﹤0.01% 2060
2018
Q4 		$72.5K Hold
30,211
– – ﹤0.01% 2470
2018
Q3 		$133K Hold
30,211
– – ﹤0.01% 2286
2018
Q2 		$218K Buy
+30,211
New +$206K ﹤0.01% 1890
2016
Q2 		– Sell
-24,810
Closed -$133K – 2699
2016
Q1 		$133K Buy
24,810
+4,569
+23% +$26.6K ﹤0.01% 2384
2015
Q4 		$176K Hold
20,241
– – ﹤0.01% 2343
2015
Q3 		$170K Sell
20,241
-708
-3% -$11.3K ﹤0.01% 2393
2015
Q2 		$369K Buy
+20,949
New +$269K ﹤0.01% 1961

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s SRNE Position: Q1 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 28,609 shares — an estimated $25.3K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in SRNE in Q2 2015 and held it in 23 quarters. The position peaked at $719K in Q3 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 28,609 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $25.3K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 23 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Sorrento Therapeutics, Inc. position peaked at $719K in Q3 2020.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2023, filed 15 May 2023.